PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise

References

• Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143–153. doi:10.1038/nrclinonc.2013.10
   PubMed Web of Science ®Google Scholar
• Schatz JH. Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin’s lymphoma: results, biology, and development strategies. Curr Oncol Rep. 2011;13(5):398. doi:10.1007/s11912-011-0187-7
   PubMed Web of Science ®Google Scholar
• Kikushige Y. Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies. J Clin Exp Hematop. 2020;60(4):146–158. doi:10.3960/jslrt.20036
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. doi:10.1182/blood-2017-09-806398
   PubMed Web of Science ®Google Scholar
• Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020;383(5):460–473. doi:10.1056/NEJMra1908213
   PubMed Web of Science ®Google Scholar
• Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. The Lancet. 2018;391(10129):1524–1537. doi:10.1016/S0140-6736(18)30422-7
   PubMed Web of Science ®Google Scholar
• Barnett AK, Waddell JA, Solimando DA. Idelalisib and rituximab regimen. Hosp Pharm. 2017;52(3):187–190. doi:10.1310/hpj5203-187
   PubMedGoogle Scholar
• Dreger P, Schetelig J, Andersen N, et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014;124(26):3841–3849. doi:10.1182/blood-2014-07-586826
   PubMed Web of Science ®Google Scholar
• Ghia P, Pluta A, Wach M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849–2861. doi:10.1200/JCO.19.03355
   PubMed Web of Science ®Google Scholar
• Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298–310. doi:10.1016/S0140-6736(16)32407-2
   PubMed Web of Science ®Google Scholar
• Al Juhaishi T, Yazbeck V. Choosing the right pharmacotherapy for non-Hodgkin’s lymphoma: does one size fit all? Expert Opin Pharmacother. 2019;20(7):773–775. doi:10.1080/14656566.2019.1582643
   PubMed Web of Science ®Google Scholar
• Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: B-cell non-Hodgkin lymphomas. Expert Rev Hematol. 2017;10(5):405–415. doi:10.1080/17474086.2017.1318053
   PubMed Web of Science ®Google Scholar
• Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316–327. doi:10.1002/ajh.25696
   PubMed Web of Science ®Google Scholar
• Casulo C, Dixon JG, Le-Rademacher J, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(11):1684–1693. doi:10.1182/blood.2020010263
   PubMed Web of Science ®Google Scholar
• Sindel A, Al-Juhaishi T, Yazbeck V. Marginal zone lymphoma: state-of-the-art treatment. Curr Treat Options Oncol. 2019;20(12):90. doi:10.1007/s11864-019-0687-5
   PubMed Web of Science ®Google Scholar
• Luminari S, Merli M, Rattotti S, et al. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. Blood. 2019;134(10):798–801. doi:10.1182/blood.2019001088
   PubMed Web of Science ®Google Scholar
• Leslie LA, Skarbnik AP, Bejot C, Stives S, Feldman TA, Goy AH. Targeting indolent non-Hodgkin lymphoma. Expert Rev Hematol. 2017;10(4):299–313. doi:10.1080/17474086.2017.1303374
   PubMed Web of Science ®Google Scholar
• Ramadani F, Bolland DJ, Garcon F, et al. The PI3K Isoforms p110α and p110δ are essential for pre–B cell receptor signaling and B cell development. Sci Signal. 2010;3(134):ra60–ra60. doi:10.1126/scisignal.2001104
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science. 2002;297(5583):1031–1034. doi:10.1126/science.1073560
   PubMed Web of Science ®Google Scholar
• Hus I, Puła B and Robak T. (2022). PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives. Cancers, 14(6), 1571 10.3390/cancers14061571
   PubMed Web of Science ®Google Scholar
• Tuveson David A, Carter Robert H, Soltoff Stephen P, Fearon douglas T. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science. 1993;260(5110):986–989. doi:10.1126/science.7684160
   PubMed Web of Science ®Google Scholar
• Kong D, Yamori T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci. 2008. doi:10.1111/j.1349-7006.2008.00891.x
   Web of Science ®Google Scholar
• Abdelrasoul H, Werner M, Setz CS, Okkenhaug K, Jumaa H. PI3K induces B-cell development and regulates B cell identity. Sci Rep. 2018;8(1):1327. doi:10.1038/s41598-018-19460-5
   PubMedGoogle Scholar
• Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci. 2005;30(4):194–204. doi:10.1016/j.tibs.2005.02.008
   PubMed Web of Science ®Google Scholar
• Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009;139(3):573–586. doi:10.1016/j.cell.2009.08.041
   PubMed Web of Science ®Google Scholar
• Westin JR. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk. 2014;14(5):335–342. doi:10.1016/j.clml.2014.01.007
   PubMed Web of Science ®Google Scholar
• Crank MC, Grossman JK, Moir S, et al. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. J Clin Immunol. 2014;34(3):272–276. doi:10.1007/s10875-014-0012-9
   PubMed Web of Science ®Google Scholar
• Gulmann C, Espina V, Petricoin E, et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res. 2005;11(16):5847–5855. doi:10.1158/1078-0432.CCR-05-0637
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Hansson U, Olsson M, et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy: p-AKT Expression in DLBCL. Br J Haematol. 2010;149(4):560–568. doi:10.1111/j.1365-2141.2010.08123.x
   PubMed Web of Science ®Google Scholar
• Fang X, Zhou X, Wang X. Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma. Biomark Res. 2013;1(1):30. doi:10.1186/2050-7771-1-30
   PubMedGoogle Scholar
• Lampson BL, Brown JR. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs. 2017;26(11):1267–1279. doi:10.1080/13543784.2017.1384815
   PubMed Web of Science ®Google Scholar
• Fruman DA. Targeting PI3K-gamma in non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):932–934. doi:10.1200/JCO.19.00215
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov. 2021;20(10):741–769. doi:10.1038/s41573-021-00209-1
   PubMed Web of Science ®Google Scholar
• Richardson NC, Kasamon Y, Pazdur R, Gormley N. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol. 2022;23(5):563–566. doi:10.1016/S1470-2045(22)00200-5
   PubMed Web of Science ®Google Scholar
• FDA. Research C for DE and. FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib). FDA; 2022. Availabe from: https://www.fda.gov/drugs/development-approval-process-drugs/fda-investigating-possible-increased-risk-death-lymphoma-medicine-ukoniq-umbralisib. Accessed June 8, 2022.
   Google Scholar
• Markham A. Idelalisib: first global approval. Drugs. 2014;74(14):1701–1707. doi:10.1007/s40265-014-0285-6
   PubMed Web of Science ®Google Scholar
• Markham A. Copanlisib: first global approval. Drugs. 2017;77(18):2057–2062. doi:10.1007/s40265-017-0838-6
   PubMed Web of Science ®Google Scholar
• Blair HA. Duvelisib: first global approval. Drugs. 2018;78(17):1847–1853. doi:10.1007/s40265-018-1013-4
   PubMed Web of Science ®Google Scholar
• Dhillon S, Keam SJ. Umbralisib: first Approval. Drugs. 2021;81(7):857–866. doi:10.1007/s40265-021-01504-2
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007. doi:10.1056/NEJMoa1315226
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018. doi:10.1056/NEJMoa1314583
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–3905. doi:10.1200/JCO.2017.75.4648
   PubMed Web of Science ®Google Scholar
• Dong S, Guinn D, Dubovsky JA, et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood. 2014;124(24):3583–3586. doi:10.1182/blood-2014-07-587279
   PubMed Web of Science ®Google Scholar
• Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912–922. doi:10.1200/JCO.18.00915
   PubMed Web of Science ®Google Scholar
• Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446–2455. doi:10.1182/blood-2018-05-850461
   PubMed Web of Science ®Google Scholar
• Meeting of the Oncologic Drugs Advisory Committee (ODAC) - Day 2; 2022. Available from: https://www.youtube.com/watch?v=cjkgIpaxHlI. Accessed December 27, 2022.
   Google Scholar
• Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a Dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol. 2021;39(15):1609–1618. doi:10.1200/JCO.20.03433
   PubMed Web of Science ®Google Scholar
• Gribben JG, Jurczak W, Jacobs RW, et al. Umbralisib plus ublituximab (U2) is superior to obinutuzumab plus chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): results from the Phase 3 Unity-CLL Study. Blood. 2020;136(1):37–39. doi:10.1182/blood-2020-134783
   Google Scholar
• Phillips TJ, Michot JM, Ribrag V. Can next-generation PI3K inhibitors unlock the full potential of the class in patients with B-cell lymphoma? Clin Lymphoma Myeloma Leuk. 2021;21(1):8–20.e3. doi:10.1016/j.clml.2020.08.022
   PubMed Web of Science ®Google Scholar
• Greenwell IB, Flowers CR, Blum KA, Cohen JB. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow. Expert Rev Anticancer Ther. 2017;17(3):271–279. doi:10.1080/14737140.2017.1285702
   PubMed Web of Science ®Google Scholar
• Shah A, Barrientos J. Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: a Narrative Review on Duvelisib. OncoTargets Ther. 2021;14:2109–2119. doi:10.2147/OTT.S189032
   PubMed Web of Science ®Google Scholar
• Ma S, Chan RJ, Gu L, et al. Retrospective analysis of the impact of adverse event–triggered idelalisib interruption and dose reduction on clinical outcomes in patients with relapsed/refractory B-cell malignancies. Clin Lymphoma Myeloma Leuk. 2021;21(5):e432–e448. doi:10.1016/j.clml.2020.12.016
   PubMed Web of Science ®Google Scholar
• Wagner-Johnston ND, Sharman J, Furman RR, et al. Idelalisib immune-related toxicity is associated with improved treatment response. Leuk Lymphoma. 2021;62(12):2915–2920. doi:10.1080/10428194.2021.1948038
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297–311. doi:10.1016/S1470-2045(16)30671-4
   PubMed Web of Science ®Google Scholar
• Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37(16):1391–1402. doi:10.1200/JCO.18.01460
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Capra M, Özcan M, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):678–689. doi:10.1016/S1470-2045(21)00145-5
   PubMed Web of Science ®Google Scholar
• Davids MS, O’Connor OA, Jurczak W, et al. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies. Blood Adv. 2021;5(23):5332–5343. doi:10.1182/bloodadvances.2021005132
   PubMed Web of Science ®Google Scholar
• FDA. Commissioner O of the. Ukoniq (Umbralisib): drug safety communication - FDA investigating possible increased risk of death with lymphoma. FDA; 2022. Available from: https://www.fda.gov/safety/medical-product-safety-information/ukoniq-umbralisib-drug-safety-communication-fda-investigating-possible-increased-risk-death-lymphoma. Accessed June 23, 2022.
   Google Scholar
• Rao VK, Webster S, Sediva A, et al. Interim analysis of safety and hematological parameters of an ongoing long-term open-label extension study of investigational PI3Kδ inhibitor leniolisib for patients with activated PI3K Delta Syndrome (APDS) through December 2021. Blood. 2022;140(1):1643–1645. doi:10.1182/blood-2022-160334
   Google Scholar
• Zelenetz AD, Jagadeesh D, Kenkre VP, et al. The pi3kδ inhibitor me-401 ± rituximab in relapsed/refractory (R/r) follicular lymphoma (FL), chronic lymphocytic leukemia (Cll), and small lymphocytic lymphoma(Sll). Hematol Oncol. 2019;37:176–177. doi:10.1002/hon.133_2629
   PubMedGoogle Scholar
• Pagel JM, Soumerai JD, Reddy N, et al. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022;23(8):1021–1030. doi:10.1016/S1470-2045(22)00333-3
   PubMed Web of Science ®Google Scholar